Help Ensure the Safe Use of Secondary Hyperparathyroid Meds

February 2018

The new med etelcalcetide (Parsabiv, PAR-sah-biv) will raise questions about treating hyperparathyroidism in dialysis patients.

Hyperphosphatemia and low vitamin D in renal patients leads to hypocalcemia...which stimulates parathyroid hormone (PTH) release.

This is why the first steps in treating patients with elevated PTH are to control high phosphate and treat vitamin D deficiency.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote